Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters
Facility to support clinical manufacturing for Vor Bio’s novel cell and genome engineering pipeline while reducing the time and cost...
Clinical Trial
Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film for European and MENA Markets
WARREN, N.J., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive”), a pharmaceutical company advancing medicines to...
SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against Multiple COVID-19 Variants Including Omicron
SAB’s fully-human polyclonal antibody platform maintains its efficacy against multiple variants of several highly mutating virusesSIOUX FALLS, S.D., Sept. 28,...
Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
Twenty-four week interim analysis on approximately 160 subjects planned for Q1 2023GAITHERSBURG, Md., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Altimmune,...
Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases...
Velocity Clinical Research reveals findings from US patient survey on decentralization in clinical research
Velocity Clinical Research: The US Patient Survey 2022, Decentralization in Clinical Research. Dr G. Paul Evans, Chief Executive and President...
KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)
SDX administered at single doses of 80 mg and 200 mg was well-tolerated CELEBRATION, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE)...
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announced that apabetalone’s future...
Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts
Dr. Dreismann, Former Roche Molecular Diagnostics CEO, and Mr. Tibbitts, a Highly-accomplished Life-Sciences Executive, Provide Extensive Experience in Diagnostics and...
KBio Announces Strategic Collaboration with Leaf Expression Systems to Enhance Development and Production of Novel Therapeutics
Collaboration to focus on new plant lines and other plant-based technologies aimed at efficient production scale-up of KBio's current and...
Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer
Clinical program advancement represents key milestone for Cornerstone underscoring its commitment to the development of lead compound, devimistat, in pancreatic...
BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference
MELVILLE, NY., Sept. 28, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company...
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at the Fondazione Prada in Milan
“Effect of nasal anti-CD3 (foralumab) in animal model of Progressive Multiple Sclerosis (MS)” poster exhibit“Effect of nasal anti-CD3 (foralumab) in...
Xequel Bio To Present Corporate Overview and Clinical Trial Data at Eyecelerator® at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
- Presentation Will Highlight Positive Clinical Trial Data on iNexin™ for Treatment of Corneal Injury - - Xequel Launches New...
Oncternal Therapeutics Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL
SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...
Altamira Therapeutics Re-launches Bentrio in Europe for Allergic Rhinitis
Bentrio USA Altamira Therapeutics Re-launches Bentrio in Europe for Allergic RhinitisHAMILTON, BERMUDA , Sept. 27, 2022 (GLOBE NEWSWIRE) -- BentrioTM...
IMUNON to Present at Chardan’s 6th Annual Genetic Medicines Conference
LAWRENCEVILLE, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr....
Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of...
Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD
ISELIN, N.J. and CONSHOHOCKEN, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working...
Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress
Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds of approximately $12.8 millionFinancing supports...